Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Vivendy Therapeutics

Request full access

Vivendy Therapeutics is engaged in the development of enzyme replacement therapy

Basel, SwitzerlandFounded 2006Biotechnology

About Vivendy Therapeutics

Vivendy Therapeutics Ltd. operated as a biopharmaceutical firm with a sharp focus on addressing a significant unmet medical need: Morbus Morquio, also known as Mucopolysaccharidosis IVA (MPS IVA). Founded in March 2006 as a spin-off from Inotech Biotechnologies AG, the Basel-based company dedicated its efforts to developing an enzyme replacement therapy (ERT) for this rare, inherited lysosomal storage disease. The core of its business was the development of a therapeutic for a disease caused by the deficient activity of the N-acetylgalactosamine-6-sulfatase (GALNS) enzyme, leading to severe clinical consequences.

The company's strategy centered on creating a biopharmaceutical drug for a condition with no existing therapy. This positioned Vivendy's product to potentially receive "orphan drug status," a designation that provides incentives for the development of treatments for rare diseases. The business model relied on raising significant venture capital to fund the lengthy and expensive process of drug development, from preclinical research to market introduction. A major financial milestone was achieved on June 18, 2008, when the company secured $30.5 million in a Series A funding round. This financing was led by a syndicate of prominent life science investors, including Life Sciences Partners, EQT, TVM Capital, BioMedPartners, and Aescap Venture. The then-CEO, Dr. Roland Toder, stated that this capital was intended to be sufficient to bring their lead product all the way to market introduction.

Vivendy Therapeutics' approach involved using a genetically modified form of the natural enzyme to effectively treat Morbus Morquio patients. The company's mission was to navigate the complex development path toward registration and provide a therapy for patients as quickly as possible. Despite securing substantial funding and having a clear development strategy, the company was reportedly liquidated in 2012 and is now considered deadpooled.

Source: Dealroom company data

At a glance

Status
Closed
Employees
1
Open positions
None listed

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jun 2008 $31M $122M BioMedVC · TVM Capital Life Science · EQT Life Sciences —
SERIES AEquity / VC Dec 2007 $15M $62M BioMedVC · EQT Life Sciences —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Vivendy Therapeutics website traffic

Latest recorded traffic for Vivendy Therapeutics is 0 monthly website visits. Vivendy Therapeutics's team grew 0% over the past year.

Latest monthly visits0 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Vivendy Therapeutics in the Basel ecosystem

Live from Dealroom

The Vivendy Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • BioMedVC
  • EQT Life Sciences
  • TVM Capital Life Science
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇭 Switzerland · Basel HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Vivendy Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Vivendy Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.